Pharmaceutical Research and Consulting, Inc.

Dallas Allergy and Asthma Center

Asthma

Rhinitis

Allergic Rhinitis

Cough

Perennial Allergic Rhinitis

Chronic Cough

beclomethasone dipropionate

Bradanicline

Ciclesonide

Daclizumab

Attenua

Facet Biotech

Sumitomo Pharma

Teva Pharmaceuticals

Uniquity One (UNI)

condition

allSponsorName

DevPro Biopharma

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma.

A Study to Evaluate Solriktug in Adult Participants With Asthma

Dallas Allergy and Asthma Center | Pharmaceutical Research and Consulting, Inc.

Site insights

Work at this site?

Active trials

A Study to Evaluate Solriktug in Adult Participants With Asthma (RAINIER)

Trial sponsors